AKAMAI TECHNOLOGIES INC (AKAM) earnings date, results and what the price requires
Nasdaq · SEC CIK 0001086222 · SEC filings checked Oct 17, 2026
Previous results (SEC filings)
| Quarter ended | Reported | Revenue | Net income | Diluted EPS | Source |
|---|---|---|---|---|---|
| Jun 30, 2026 | Aug 6, 2026 | $1.10B | $79.4M | $0.52 | Filing |
| Mar 31, 2026 | May 7, 2026 | $1.07B | $106.3M | $0.71 | Filing |
| Dec 31, 2025 | Feb 19, 2026 | $1.09B | $85.1M | $0.57 | Filing |
| Sep 30, 2025 | Nov 6, 2025 | $1.05B | $140.2M | $0.97 | Filing |
| Jun 30, 2025 | Aug 7, 2025 | $1.04B | $103.6M | $0.71 | Filing |
| Mar 31, 2025 | May 8, 2025 | $1.02B | $123.2M | $0.82 | Filing |
| Dec 31, 2024 | Feb 20, 2025 | $1.02B | $139.9M | $0.92 | Filing |
| Sep 30, 2024 | Nov 7, 2024 | $1.00B | $57.9M | $0.38 | Filing |
What would AKAMAI TECHNOLOGIES INC have to report for its valuation to change?
At $92.32, with a 9.0% required return and a 18× earnings multiple in 5 years, earnings per share must grow about 23.3% a year, to $7.89. On that path the next quarter needs diluted EPS near $1.20, against $0.97 in the quarter ended Sep 30, 2025.
Compare buying at the last close now with waiting for results: if the report moves the growth the price requires, the entry price you would accept changes with it.
| Result | Original | Yours |
|---|---|---|
| Required EPS growth / year | 23.3% | 23.3% |
| EPS needed in final year | $7.89 | $7.89 |
Changed: nothing yet. Model: EPS × (1+g)^years × final P/E, discounted at the required return, equals today's price. Inputs: SEC diluted EPS and the dated close above.
Prepare for earnings across my investments — $399/month
Keep working models for the companies you follow, compare your expectations with reported results, and review what changes your investment decision. AKAM goes in with your buy-or-wait comparison and assumptions preserved.
Figures come from SEC EDGAR XBRL filings. Dates marked "estimated" are calculated from the company's past results filings and are not confirmed. Not investment advice.